Photo taken from Ben Ponvilawan/X
Oct 12, 2024, 14:31
Ben Ponvilawan: HCC Etiology’s Impact on Positive Results in the CARES-310 Trial
Ben Ponvilawan, Doctor of Medicine at UMKC Internal Medicine Residency Program, shared on X:
” Our correspondence is now available on The Lancet! Differences in HCC etiology may contribute to the positive result of camrelizumab plus rivoceranib in CARES-310 trial, in contrast to other IO+TKI trials.
Thank you Marc Roth, Saint Luke’s Cancer Institute for the support.”
Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12